Intervention

eribulin

ClinicalTrials.gov intervention label

Clinical trials5

Recruiting1

Common conditions13

Lead sponsors shown5

Clinical trials

5 shown

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)NCT05824975 · 2023-05-30

Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119)NCT02555657 · 2015-10-13

Detect V / CHEVENDO (Chemo vs. Endo)NCT02344472 · 2015-09-01

Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast CancerNCT01912963 · 2013-09-01

Study of Neoadjuvant Carboplatin, Eribulin and Trastuzumab for Operable HER2 Positive Breast CancerNCT01388647 · 2011-08-01

Common conditions

Metastatic Breast Cancer2 Advanced Solid Tumor1 Colorectal Cancer (CRC)1 Cutaneous Melanoma1 Hepatocellular Carcinoma (HCC)1 HER-2 Positive Breast Cancer1 HER2 Negative Breast Cancer1 HER2-positive Breast Cancer1 Metastatic Solid Tumor1 Metastatic Triple Negative Breast Cancer1 Platinum-resistant Ovarian Cancer (PROC)1 Renal Cell Carcinoma (RCC)1 Soft Tissue Sarcoma (STS)1

Leading sponsors

Dana-Farber Cancer Institute1 GI Innovation, Inc.1 Merck Sharp & Dohme LLC1 Prof. Wolfgang Janni1 Vector Oncology1

Trial status mix

TERMINATED2

COMPLETED1

RECRUITING1

UNKNOWN1

Phase mix

PHASE23

PHASE12

PHASE32

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.